Astrana Health, Inc. announced its financial results for the fourth quarter and full year ended December 31, 2024. For the full year 2024, total revenue reached $2.034 billion, marking a 49% increase compared to 2023. Adjusted EBITDA for the full year was $170.1 million, up 10% from the previous year, while net income attributable to Astrana Health, Inc. was $43.171 million, a decrease from $48.361 million in 2023.
In the fourth quarter of 2024, the company reported total revenue of $665.2 million, an 88% increase over Q4 2023. Adjusted EBITDA for the quarter was $48.9 million, a 10% increase year-over-year. Net income attributable to Astrana Health, Inc. for Q4 2024 was $1.062 million, down from $14.292 million in Q4 2023.
Astrana Health provided its full-year 2025 guidance, projecting total revenue between $2.5 billion and $2.7 billion and Adjusted EBITDA between $170 million and $190 million. This guidance includes approximately $15 million in expected costs for strategic investments in automation and AI, as well as integration costs for planned acquisitions, but excludes contributions from any acquisitions not yet closed.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.